{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:37:03Z","timestamp":1793205423735,"version":"4.5.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To evaluate how often women with a history of breast cancer who are taking hormone therapy (HT) filled prescriptions for topical estrogens and whether this frequency varied over time and by type of HT used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>We performed a retrospective cohort study using medical and outpatient drug claims from a large commercial claims database for the years 2010\u20132015. Women younger than age 65 years taking HT for breast cancer were classified as users of 1) tamoxifen only, 2) aromatase inhibitor(s) only, or 3) any other or multiple HTs. Our outcome variable was filling a prescription for topical estrogen in a given year. We used multivariable logistic regression models estimated with generalized estimating equations to determine whether the fill rate varied over time and by HT category adjusting for age, receipt of surgical or radiation treatment, types of outpatient health care provider visits, and comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>We identified 352,118 records from 176,012 unique patients (mean age 54.3 years, range 18\u201364 years) who met eligibility criteria. Aromatase inhibitors were used more commonly (56.0% of patient-years) than tamoxifen (38.8%). Overall, 3.0% (range 2.9\u20133.1%) of women filled any topical estrogen prescription in a given calendar year. More than half of filled topical estrogen prescriptions were for tablets (57.0%) with the remainder for creams (25.8%) and rings (17.3%). In adjusted analyses, the fill rate for women taking tamoxifen was significantly less (2.4%; 95% CI 2.3\u20132.5%) than for women taking aromatase inhibitors (3.3%; 95% CI 3.2\u20133.4%). There was a small but statistically significant increase in fill rates across years (odds ratio 1.03, 95% CI 1.02\u20131.04).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>A small proportion of women with a history of breast cancer who were taking HT filled a topical estrogen prescription, with significant differences by type of HT. More evidence is needed to inform national guidelines regarding safety and appropriate use of topical estrogens in this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000002914","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T21:04:56Z","timestamp":1539119096000},"page":"1137-1142","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Topical Estrogen Prescription Fill Rates for Women With a History of Breast Cancer Who Are Taking Hormone Therapy"],"prefix":"10.1097","volume":"132","author":[{"given":"Joseph H.","family":"Huntley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee A.","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L.","family":"Blackford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluseyi","family":"Aliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig E.","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261028","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1200\/JCO.2015.65.9573","article-title":"Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression","volume":"34","author":"Burstein","year":"2016","journal-title":"J Clin Oncol"},{"key":"R2-20261028","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1529-8019.2010.01354.x","article-title":"Atrophic vaginitis","volume":"23","author":"Stika","year":"2010","journal-title":"Dermatol Ther"},{"key":"R3-20261028","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3109\/13697137.2013.819327","article-title":"Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer","volume":"17","author":"Kyvernitakis","year":"2014","journal-title":"Climacteric"},{"key":"R4-20261028","first-page":"40","article-title":"Estrogen and its effect on vaginal atrophy in post-menopausal women","volume":"27","author":"Kelley","year":"2007","journal-title":"Urol Nurs"},{"key":"R5-20261028","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3816\/CBC.2009.n.020","article-title":"Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer","volume":"9","author":"Chin","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"R6-20261028","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/GME.0b013e31826560da","article-title":"Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer","volume":"20","author":"Baumgart","year":"2013","journal-title":"Menopause"},{"key":"R7-20261028","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1111\/jsm.12684","article-title":"Sexual problems during the first 2 years of adjuvant treatment with aromatase inhibitors","volume":"11","author":"Schover","year":"2014","journal-title":"J Sex Med"},{"issue":"suppl 1","key":"R8-20261028","first-page":"S55","article-title":"Premature menopause in young breast cancer: effects on quality of life and treatment interventions","volume":"5","author":"Rosenberg","year":"2013","journal-title":"J Thorac Dis"},{"key":"R9-20261028","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/jnci\/djr541","article-title":"Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review","volume":"104","author":"Howard-Anderson","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"R11-20261028","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/annonc\/mdj127","article-title":"Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors","volume":"17","author":"Kendall","year":"2006","journal-title":"Ann Oncol"},{"key":"R12-20261028","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/13697137.2011.642427","article-title":"Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients","volume":"15","author":"Kunovac Kallak","year":"2012","journal-title":"Climacteric"},{"key":"R13-20261028","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JOP.2011.000352","article-title":"Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator","volume":"8","author":"Wills","year":"2012","journal-title":"J Oncol Pract"},{"key":"R14-20261028","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/cmt.6.1.45.52","article-title":"A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer","volume":"6","author":"Dew","year":"2003","journal-title":"Climacteric"},{"key":"R15-20261028","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jamaoncol.2016.3904","article-title":"Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial","volume":"3","author":"Melisko","year":"2017","journal-title":"JAMA Oncol"},{"key":"R16-20261028","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1097\/AOG.0000000000001351","article-title":"The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Committee Opinion No. 659. American College of Obstetricians and Gynecologists","volume":"127","year":"2016","journal-title":"Obstet Gynecol"},{"key":"R20-20261028","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"R21-20261028","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/1536867X1201200209","article-title":"Using the margins command to estimate and interpret adjusted predictions and marginal effects","volume":"12","author":"Williams","year":"2012","journal-title":"Stata J"},{"key":"R22-20261028","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/j.ejca.2005.07.015","article-title":"Vaginal oestrogen therapy after breast cancer: is it safe?","volume":"41","author":"Ponzone","year":"2005","journal-title":"Eur J Cancer"},{"key":"R23-20261028","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/AOG.0b013e31824e12ce","article-title":"Management of gynecologic issues in women with breast cancer. Practice Bulletin No. 126. American College of Obstetricians and Gynecologists","volume":"119","year":"2012","journal-title":"Obstet Gynecol"},{"key":"R24-20261028","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/00001813-200409000-00003","article-title":"Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients","volume":"15","author":"Morales","year":"2004","journal-title":"Anticancer Drugs"},{"key":"R25-20261028","first-page":"3199","article-title":"Effective patient-provider communication about sexual concerns in breast cancer: a qualitative study","volume":"25","author":"Reese","year":"2017","journal-title":"Support Care Cancer"},{"key":"R26-20261028","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/pon.3736","article-title":"Sexual health communication between cancer survivors and providers: how frequently does it occur and which providers are preferred?","volume":"24","author":"Sporn","year":"2015","journal-title":"Psychooncology"},{"key":"R27-20261028","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1743-6109.2012.02702.x","article-title":"What we don't talk about when we don't talk about sex: results of a national survey of U.S. obstetrician\/gynecologists","volume":"9","author":"Sobecki","year":"2012","journal-title":"J Sex Med"},{"key":"R28-20261028","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s11606-010-1253-9","article-title":"Primary medication non-adherence: analysis of 195,930 electronic prescriptions","volume":"25","author":"Fischer","year":"2010","journal-title":"J Gen Intern Med"},{"key":"R29-20261028","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1472-6963-7-55","article-title":"Patient adherence to medical treatment: a review of reviews","volume":"7","author":"van Dulmen","year":"2007","journal-title":"BMC Health Serv Res"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006250-201811000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:01:27Z","timestamp":1793203287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006250-201811000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000002914","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"2018-05-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}